Current developments of gene therapy in human diseases.
AAV
CRISPR–Cas
clinical trials
gene therapy
human diseases
Journal
MedComm
ISSN: 2688-2663
Titre abrégé: MedComm (2020)
Pays: China
ID NLM: 101769925
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
received:
10
09
2023
revised:
10
06
2024
accepted:
11
06
2024
medline:
19
8
2024
pubmed:
19
8
2024
entrez:
19
8
2024
Statut:
epublish
Résumé
Gene therapy has witnessed substantial advancements in recent years, becoming a constructive tactic for treating various human diseases. This review presents a comprehensive overview of these developments, with a focus on their diverse applications in different disease contexts. It explores the evolution of gene delivery systems, encompassing viral (like adeno-associated virus; AAV) and nonviral approaches, and evaluates their inherent strengths and limitations. Moreover, the review delves into the progress made in targeting specific tissues and cell types, spanning the eye, liver, muscles, and central nervous system, among others, using these gene technologies. This targeted approach is crucial in addressing a broad spectrum of genetic disorders, such as inherited lysosomal storage diseases, neurodegenerative disorders, and cardiovascular diseases. Recent clinical trials and successful outcomes in gene therapy, particularly those involving AAV and the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated proteins, are highlighted, illuminating the transformative potentials of this approach in disease treatment. The review summarizes the current status of gene therapy, its prospects, and its capacity to significantly ameliorate patient outcomes and quality of life. By offering comprehensive analysis, this review provides invaluable insights for researchers, clinicians, and stakeholders, enriching the ongoing discourse on the trajectory of disease treatment.
Identifiants
pubmed: 39156766
doi: 10.1002/mco2.645
pii: MCO2645
pmc: PMC11329757
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e645Informations de copyright
© 2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.
Déclaration de conflit d'intérêts
The authors have no conflict of interest to disclose.